Hypothesis: Tim-3/Galectin-9, A New Pathway for Leukemia Stem Cells Survival by Promoting Expansion of Myeloid-Derived Suppressor Cells and Differentiating into Tumor-Associated Macrophages

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 273-277

  Gao, Lei ^a   Yu, Shicang ^a   Zhang, Xi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Leukemic stem cells; Myeloid derived suppressor cells; T cell immunoglobulin mucin 3; Tumor associated macrophages

Indexed keywords

GALECTIN; HAVCR2 PROTEIN, HUMAN; LGALS9 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER STEM CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; HUMAN; MACROPHAGE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; GALECTINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MACROPHAGES; MEMBRANE PROTEINS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84906216640     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9900-0     Document Type: Article

References (39)

1. O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Coutre, S. E., Damon, L. E., et al. (2011). Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network, 9, 280-317.
2. Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., et al. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
3. Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood, 112, 4793-4807.
4. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111.
5. O'Brien, C. A., Kreso, A., & Jamieson, C. H. M. (2010). Cancer stem cells and self-renewal. Clinical Cancer Research, 16, 3113-3120.
6. Hope, K. J., Jin, L., & Dick, J. E. (2004). Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology, 5, 738-743.
7. Rico, J. F., Hassane, D. C., & Guzman, M. L. (2012). Acute myelogenous leukemia stem cells: from bench to bedside. Cancer Lett. doi: 10. 1016/j. canlet. 2012. 05. 034.
8. Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology, 25, 1315-1321.
9. Konopleva, M. Y., & Jordan, C. T. (2011). Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting. Journal of Clinical Oncology, 29, 591-599.
10. Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., et al. (2010). Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology, 28, 275-280.
11. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730-737.
12. Costello, R. T., Mallet, F., Gaugler, B., Sainty, D., Arnoulet, C., Gastaut, J., et al. (2000). Human acute myeloid leukemia CD34 +/CD38 - progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Research, 60, 4403-4411.
13. Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine, 12, 1167-1174.
14. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., et al. (2010). Identification of therapeutic targets for quiescent, chemotherapy resistant human leukemia stem cells. Science Translational Medicine, 2, 17ra19.
15. van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., et al. (2007). The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 110, 2659-2666.
16. Huntly, B. J. P., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., et al. (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell, 6, 587-596.
17. Hosen, N., Park, C. Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., et al. (2007). CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 104, 11008-11013.
18. Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D, Jr, et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286-299.
19. Xing, D., Mitchell, H., & Ira, P. (2007). New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells. Journal of Immunotherapy, 30, 607-613.
20. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., et al. (2002). Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 415, 536-541.
21. Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., et al. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 6, 1245-1252.
22. Ana, C., Anderson, A. C., & Anderson, D. E. (2006). TIM-3 in autoimmunity. Current Opinion in Immunology, 18, 665-669.
23. Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C., & Kuchroo, V. K. (2011). Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in Immunology, 32, 345-349.
24. Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., et al. (2009). Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood, 113, 3821-3830.
25. Kikushige, Y., Shima, T., Takayanagi, S., Urata, S., Miyamoto, T., Iwas, H., et al. (2010). TIM-3 Is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell, 7, 708-717.
26. Kikushige, Y., & Akashi, K. (2012). TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Annals of the New York Academy of Sciences, 1266, 118-123.
27. Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., et al. (2011). Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America, 108, 5009-5014.
28. Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 9, 162-174.
29. Dardalhon, V., Anderson, A. C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D. H., et al. (2010). Tim-3/Galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b + Ly-6G + myeloid Cells. The Journal of Immunology, 185, 1383-1392.
30. Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141, 39-51.
31. Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004). Antigen-specific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. The Journal of Immunology, 172, 989-999.
32. Huang, Y. H., Snuderl, M., & Jain, R. K. (2011). Polarization of tumor-associated Macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell, 19, 1-2.
33. Lewis, C. E., & Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66, 605-612.
34. Mantovani, A., & Sica, A. (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology, 22, 231-237.
35. Quatromoni, J. G., & Eruslanov, E. (2012). Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. American Journal of Translational Research, 4, 376-389.
36. Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T. H., Xiang, R., et al. (2013). Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway. Stem Cells, 31, 248-258.
37. Lane, S. W., Wang, Y. J., Celso, C. L., Ragu, C., Bullinger, L., Sykes, S. M., et al. (2011). Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood, 118, 2849-2856.
38. Galdiero, M. R., Garlanda, C., Jaillon, S., Marone, G., & Mantovani, A. (2013). Tumor Associated Macrophages and Neutrophils in Tumor Progression. Journal of Cellular Physiology, 228, 1404-1412.
39. Jaiswal, S., Jamieson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138, 271-285.